Xevudy (Sotrovimab), has today been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to be safe and effective
Image: POOL/AFP via Getty Images)
A new treatment found to cut the risk of death from Covid by nearly 80 per cent has been approved in the UK.
Xevudy (Sotrovimab), has today been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to be safe and effective.
The antibody treatment is most effective during the early stages of coronavirus illness, and has been authorised for use by people most at risk of serious illness.
In a statement the agency said that studies found it can reduce the risk of preventing infections requiring hospitalisation or death by 79 per cent.
It said: “In a clinical trial, a single dose of the monoclonal antibody was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection.
“Based on the clinical trial data, sotrovimab is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible and within five days of symptom onset.”
Sotrovimab, which was developed by pharmaceutical firms GSK and Vir Biotechnology, works by binding to the spike protein on the outside of the Covid-19 virus.
This prevents the virus from attaching to and entering human cells, so that it cannot replicate in the body.
It has been authorised for people with Covid who have at least one risk factor which might cause them to develop serious illness – like age, obesity, heart disease and diabetes.
MHRA chief executive Dr June Raine said: “I am pleased to say that we now have another safe and effective COVID-19 treatment, Xevudy (sotrovimab), for those at risk of developing severe illness.
“This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19, and signals another significant step forward in our fight against this devastating disease.
“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA have conducted a robust and thorough assessment of all the available data.”
We’ll be bringing you the very latest updates, pictures and video on this breaking news story.
Please check back regularly for updates on this developing story HERE . Get email updates on
the day’s biggest stories straight to your inbox by signing up for our newsletters .
Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you by following The Mirror every time you see our name.
Follow The Mirror on Google News – CLICK HERE and click the star
Follow The Mirror on Apple News – CLICK HERE available on Apple devices
Follow The Mirror on Flipboard – CLICK HERE and click follow
Keep up-to-date with your must-see news, features, videos and pictures throughout the day by following us on Facebook at facebook.com/dailymirror
See all our social accounts you can follow here: mirror.co.uk/social